Impact of diabetes on the predictive value of heart failure biomarkers

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Alonso, Nuria ^a   Lupón, Josep ^a,b   Barallat, Jaume ^a   de Antonio, Marta ^a   Domingo, Mar ^a   Zamora, Elisabet ^a,b   Moliner, Pedro ^a   Galán, Amparo ^c   Santesmases, Javier ^a   Pastor, Cruz ^a   Mauricio, Dídac ^a   Bayes Genis, Antoni ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Biomarkers; Diabetes mellitus; Heart failure; Prognostic; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; GALECTIN 3; HIGH SENSITIVITY C REACTIVE PROTEIN; HIGH SENSITIVITY TROPONIN T; MEMBRANE METALLOENDOPEPTIDASE; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR; TROPONIN T; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

AGED; AREA UNDER THE CURVE; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; UPREGULATION;

AGED; BIOMARKERS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TROPONIN T; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84994051882     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0470-x     Document Type: Article

References (25)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
2. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-9.
3. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105-13.
4. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699-703.
5. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. Heart. 2003;89:605-9.
6. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424-33.
7. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65-75.
8. Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail. 2014;7:96-103.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
10. Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, et al. Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS ONE. 2014;9:e85466.
11. Kranendonk ME, de Kleijn DP, Kalkhoven E, Kanhai DA, Uiterwaal CS, van derGraaf Y, Pasterkamp G, et al. Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol. 2014;13:37.
12. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J. 2015;79:1647-55.
13. Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015;14:73.
14. Parrinello CM, Lutsey PL, Ballantyne CM, Folsom AR, Pankow JS, Selvin E. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015;170:380-9.
15. Lin YH, Zhang RC, Hou LB, Wang KJ, Ye ZN, Huang T, Zhang J, Chen X, Kang JS. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016;118:140-5.
16. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, Cheng S, Fradley MG, Kretschman D, Gao W, O'Connor G, Wang TJ, Januzzi JL. Distributionand clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study. Clin Chem. 2012;58:1673-81.
17. von Scholten BJ, Reinhard H, Hansen TW, Lindhardt M, Petersen CL, Wiinberg N, Hansen PR, Parving HH, Jacobsen PK, Rossing P. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:59.
18. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8-16
19. Gori M, Gupta DK, Claggett B, Selvin E, Folsom AR, Matsushita K, et al. Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2016;39:677-85.
20. Bruno G, Landi A, Barutta F, Ghezzo G, Baldin C, Spadafora L, et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care. 2013;36:2677-82.
21. Lepojärvi ES, Piira OP, Kiviniemi AM, Miettinen JA, Kenttä T, Ukkola O, et al. Usefulness of highly sensitive troponin as a predictor of short-term outcome in patients with diabetes mellitus and stable coronary artery disease (from the ARTEMIS study). Am J Cardiol. 2016;117:515-21.
22. Yiu KH, Lau KK, Zhao CT, Chan YH, Chen Y, Zhen Z, Wong A, et al. Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2014;13:63.
23. Pascual-Figal DA, Lax A, Perez-Martinez MT, del Carmen Asensio-Lopez M, Sanchez-Mas J. GREAT Network. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54:29-35.
24. Rodrigues PG, Leite-Moreira AF, Falcão-Pires I. Myocardial reverse remodeling how far can we rewind? Am J Physiol Heart Circ Physiol. 2016;310:H1402-22.
25. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, Croes R, Verstreken S, Goethals M, de Raedt H, Sarma J, Joseph L, Vanderheyden M, Weinberg EO. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52:2166-74.